IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Kuaishou Technology / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/beijing-kuaishou-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:29725:1" rel="noopener">Kuaishou Technology (1024 HK)</a> is the second-largest short video platform by average DAUs (daily active users) in 9M20, according to iResearch. Helped by a strong reception by both institutional and retail investors, Kuaishou is likely to price at the top-end of the IPO price range of HK$105-115 per share, according to press reports. The shares will start trading on 5 February.</p><div class="content-highlight"><p>The stage seems set for Kuaishou to follow the strong post-listing performance of recent tech listings in Hong Kong and the US. Early indications suggest that Kuaishou's grey market price has hit HK$250 per share, slightly more than twice the rumoured IPO price, <a href="http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1073287/ipo-news" target="_blank" rel="noopener">according to Chinese media</a>. Our analysis suggests that a valuation of 2x the rumoured IPO price of HK$115 per share can be justified on stretched but plausible assumptions.</p></div>

Kuaishou Technology (1024 HK) is the second-largest short video platform by average DAUs (daily active users) in 9M20, according to iResearch. Helped by a strong reception by both institutional and retail investors, Kuaishou is likely to price at the top-end of the IPO price range of HK$105-115 per share, according to press reports. The shares will start trading on 5 February.The stage seems set for Kuaishou to follow the strong post-listing performance of recent tech listings in Hong Kong and the US. Early indications suggest that Kuaishou's grey market price has hit HK$250 per share, slightly more than twice the rumoured IPO price, according to Chinese media. Our analysis suggests that a valuation of 2x the rumoured IPO price of HK$115 per share can be justified on stretched but plausible assumptions.

Kuaishou IPO: Is It Worth Twice the IPO Price?

Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Bottom-Up

<p><a href="https://www.smartkarma.com/entities/m3-inc" target="_blank" data-smartkarma-citation="entities:13316:1" rel="noopener">M3 Inc (2413 JP)</a>  reported its 3QFY03/2021 results on Friday (29<sup>th</sup> January 2021) which saw both revenues and OP increasing at 40.1% and 78.5% YoY during the quarter. The reported revenues and OP both beat consensus estimates by 8.6% and 20.5% respectively.</p><p>We discuss the details below.</p>

M3 Inc (2413 JP)  reported its 3QFY03/2021 results on Friday (29th January 2021) which saw both revenues and OP increasing at 40.1% and 78.5% YoY during the quarter. The reported revenues and OP both beat consensus estimates by 8.6% and 20.5% respectively.We discuss the details below.

M3 3Q Results: Strong Growth in Earnings Driven by Medical and Overseas Businesses

APAC IPOs & Placements

Zhen Zhou, Toh

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Alibaba Health Information Tec / Equity Capital Markets

<p>Yunfeng Capital is looking to selling about US$509m worth of shares in <a href="https://www.smartkarma.com/entities/alibaba-health-information-technology-ltd" target="_blank" data-smartkarma-citation="entities:453:1" rel="noopener">Alibaba Health Information Technology (241 HK)</a> (Ali Health). Post-sell down, Yunfeng Capital will still have 30% stake in the company.</p><p>We have earlier covered Ali Health's 2020 placement and 1H results read-through (for <a href="https://www.smartkarma.com/entities/jd-health-international-inc" target="_blank" data-smartkarma-citation="entities:29677:1" rel="noopener">JD Health (6618 HK)</a>'s IPO) in:</p><ul>
<li>
<a href="https://www.smartkarma.com/insights/alibaba-health-placement-a-few-headwinds-but-multiple-tailwinds" target="_blank" data-smartkarma-citation="insights:41866" rel="noopener">Alibaba Health Placement - A Few Headwinds but Multiple Tailwinds</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/jd-health-ipo-ali-health-1h-results-read-through-and-index-inclusions" target="_blank" data-smartkarma-citation="insights:45773" rel="noopener">JD Health (京东健康) IPO - Ali Health 1H Results Read Through and Index Inclusions</a> </li>
</ul>

Yunfeng Capital is looking to selling about US$509m worth of shares in Alibaba Health Information Technology (241 HK) (Ali Health). Post-sell down, Yunfeng Capital will still have 30% stake in the company.We have earlier covered Ali Health's 2020 placement and 1H results read-through (for JD Health (6618 HK)'s IPO) in:

Alibaba Health Placement - A Few Headwinds but Multiple Tailwinds 

JD Health (京东健康) IPO - Ali Health 1H Results Read Through and Index Inclusions 


Alibaba Health Placement - Another Round of Selldown by Yunfeng

China and US Equity Analyst

Roger Xie

<ul style="list-style-type: disc;">
<li>
<a href="https://www.smartkarma.com/entities/hong-kong-exchanges-clearing" target="_blank" data-smartkarma-citation="entities:490:1" rel="noopener">HKEX (388 HK)</a> December ADT (Average Daily Turnover) re-accelerated strongly, delivering amazing 86% year-over-year growth in the month. The outperformance is helped by the rising global equity markets and strong IPO listings in Hong Kong. For the year 2020, HKEx ADT has accelerated the year-over-year growth rate to 49%, which is one the best trading volume years recently. In 2020, HKEx stock price rose 68%, outperforming Hang Seng Index down 3%. We believe HKEx momentum will continue in 2021.</li>
<li>We maintain our sanguine view on trading activities and IPO pipeline in Hong Kong market in 2021. <a href="https://www.smartkarma.com/entities/hong-kong-exchanges-clearing" target="_blank" data-smartkarma-citation="entities:490:1" rel="noopener">HKEX (388 HK)</a> will benefit from this secular trend in several ways: 1) Hong Kong market becomes de facto choice for China new economy companies for IPO and fund raising; 2) HKEx Northbound trading has become an increasing important factor as the gateway to invest in China A-share; 3) MSCI index products will continue to gain market share. We forecast Securities ADT of HK$240bn in FY 21 (Hong Kong and Stock Connect Northbound) and raise HKEx TP HKD 500. </li>
<li>HKEx announced that Calvin Tai Chi Kin has replaced Charles Li Xiaojia as its new interim Chief Executive, effective from 1st January 2021. Calvin Tai Chi Kin, a financial industry veteran, has been named HKEx' Interim CEO since last September. He will take over Charles Li Xiaojia’s responsibilities and continue his role as Co-President and Chief Operating Officer of HKEx. <p>Calvin brings a wealth of experience of more than thirty-five years to his new position. According to the media, several candidates have been considered by HKEx, but the final decision on HKEx CEO has not been reached. </p>
</li>
</ul>



HKEX (388 HK) December ADT (Average Daily Turnover) re-accelerated strongly, delivering amazing 86% year-over-year growth in the month. The outperformance is helped by the rising global equity markets and strong IPO listings in Hong Kong. For the year 2020, HKEx ADT has accelerated the year-over-year growth rate to 49%, which is one the best trading volume years recently. In 2020, HKEx stock price rose 68%, outperforming Hang Seng Index down 3%. We believe HKEx momentum will continue in 2021.
We maintain our sanguine view on trading activities and IPO pipeline in Hong Kong market in 2021. HKEX (388 HK) will benefit from this secular trend in several ways: 1) Hong Kong market becomes de facto choice for China new economy companies for IPO and fund raising; 2) HKEx Northbound trading has become an increasing important factor as the gateway to invest in China A-share; 3) MSCI index products will continue to gain market share. We forecast Securities ADT of HK$240bn in FY 21 (Hong Kong and Stock Connect Northbound) and raise HKEx TP HKD 500. 
HKEx announced that Calvin Tai Chi Kin has replaced Charles Li Xiaojia as its new interim Chief Executive, effective from 1st January 2021. Calvin Tai Chi Kin, a financial industry veteran, has been named HKEx' Interim CEO since last September. He will take over Charles Li Xiaojia’s responsibilities and continue his role as Co-President and Chief Operating Officer of HKEx. Calvin brings a wealth of experience of more than thirty-five years to his new position. According to the media, several candidates have been considered by HKEx, but the final decision on HKEx CEO has not been reached. 



HKEx (388.HK): A Blockbuster Year 2020; Becoming Regional Leader in Years Ahead; Raise TP to HK$500

<div><p><a href="https://www.smartkarma.com/entities/yidu-tech-inc" target="_blank" data-smartkarma-citation="entities:29245:1" rel="noopener">Yidu Tech Inc (2158 HK)</a> is a software company that offers healthcare solutions built on big data and artificial intelligence (AI) technologies. Yidu ranked No.1 in terms of revenue among all healthcare big data solution providers in China in 2019 with a market share of 5.0% in the healthcare big data solutions market in China, according to EY.  Yidu Tech will commence trading on Friday, 15 January. Yidu Tech priced its IPO at HK$26.30 and <a href="https://www.thestandard.com.hk/section-news/section/2/226552/US%243b-Bilibili-IPO-to-open-in-March" target="_blank" rel="noopener">opened 154% higher</a> at HK$67.00 in the grey market.</p></div><div><p>In <a href="https://www.smartkarma.com/insights/yidu-tech-ipo-initiation-patient-revolution" target="_blank" data-smartkarma-citation="insights:46392" rel="noopener">Yidu Tech IPO Initiation: Patient Revolution</a>, we stated that Yidu is an attractive play on China’s healthcare industry rising spend on IT and data services. In <a href="https://www.smartkarma.com/insights/yidu-tech-ipo-valuation-insights" target="_blank" data-smartkarma-citation="insights:46734" rel="noopener">Yidu Tech IPO: Valuation Insights</a>, we noted that the IPO price range is attractive.</p></div><div><div><div class="content-highlight"><p>Our base-case DCF derived price target of HK$40.06 per share, 52% above the IPO price. As DCF-based target prices are subject to a wide range of variability, we present a sensitivity table to help investors gauge where target prices could head. Our DCF sensitivity analysis shows that the IPO price continues to provide good upside potential. </p></div></div></div>

Yidu Tech Inc (2158 HK) is a software company that offers healthcare solutions built on big data and artificial intelligence (AI) technologies. Yidu ranked No.1 in terms of revenue among all healthcare big data solution providers in China in 2019 with a market share of 5.0% in the healthcare big data solutions market in China, according to EY.  Yidu Tech will commence trading on Friday, 15 January. Yidu Tech priced its IPO at HK$26.30 and opened 154% higher at HK$67.00 in the grey market.In Yidu Tech IPO Initiation: Patient Revolution, we stated that Yidu is an attractive play on China’s healthcare industry rising spend on IT and data services. In Yidu Tech IPO: Valuation Insights, we noted that the IPO price range is attractive.Our base-case DCF derived price target of HK$40.06 per share, 52% above the IPO price. As DCF-based target prices are subject to a wide range of variability, we present a sensitivity table to help investors gauge where target prices could head. Our DCF sensitivity analysis shows that the IPO price continues to provide good upside potential. 

China

JD Health International Inc. operates drug stores. The Company retails Chinese and Western medicines, nutrition products, health care products, and other products. JD Health International markets its products throughout China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

JD Health International (6618 HK)

Kuaishou IPO: Is It Worth Twice the IPO Price?

Kuaishou's grey market price has hit HK$250 per share, slightly more than 2x the IPO price of HK$115. Our analysis suggests that this valuation can...

Arun George

M3 3Q Results: Strong Growth in Earnings Driven by Medical and Overseas Businesses

M3 Inc. reported its 3QFY03/2021 results on Friday (29th January 2021) which saw both revenues and OP increasing at 40.1% and 78.5% YoY during the...

Shifara Samsudeen, ACMA, CGMA

Alibaba Health Placement - Another Round of Selldown by Yunfeng

Yunfeng Capital is looking to selling about US$509m worth of shares in Alibaba Health Information Technology (241 HK) (Ali Health).

Zhen Zhou, Toh

HKEx (388.HK): A Blockbuster Year 2020; Becoming Regional Leader in Years Ahead; Raise TP to HK$500

We maintain our sanguine view on trading activities and IPO pipeline in Hong Kong market in 2021and raise HKEx TP HKD 500.

Roger Xie

Yidu Tech IPO: Trading Debut

Yidu Tech priced its IPO at HK$26.30 and opened 154% higher at HK$67.00 in the grey market. Our DCF sensitivity analysis shows that the IPO price...

Arun George

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)